Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

Feb 12, 2025

BUY
$4.26 - $7.48 $2.15 Million - $3.77 Million
504,100 New
504,100 $2.4 Billion

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Bit Capital Gmb H Portfolio

Follow Bit Capital Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Bit Capital Gmb H with notifications on news.